Condition: Bipolar Depression · Sponsor: Göteborg University
An explorative, open label, single armed, flexible dose, single center, phase IIa study of 8 weeks, initiated in subjects with bipolar depression. The study will consist of 9 visits and 1 safety visit. Subjects with a primary diagnosis of bipolar disorder (type 1 or 2) currently in an acute depressive phase (i.e. bipolar depression) and being on stable medication with at least one mood stabilizer.
This description comes directly from the study's public registry record.
Elias Eriksson, Professor · + 46 709 555055 · elias.eriksson@neuro.gu.se
Steinn Steingrimsson, MD, PhD · + 46 722 448372 · steinn.steingrimsson@vgregion.se
Always discuss trial participation with your own doctor first.
| Sahlgrenska university hospital/Östra | Gothenburg, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05296356